Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03749018
Title Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kami Maddocks

B-cell lymphoma


Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.